Proteintech Group CEO, Dr. Jason Li, has always believed in an antibody market built on transparency and supplier accountability. The emergence of the ‘Reproducibility Crisis’ in the life science community has highlighted the need to address issues such as the re-branding of antibodies. Follow the link below to read Dr. Li’s most recent article that discusses how market forces has led to a lack of transparency and ultimately, faulty products in the antibody market.
Article published in Scientific American, September 2016.
Article by Dr Jason Li for Scientific American's Guest Blog
Only 50 percent of the antibodies produced commercially for biomedical research actually do what they're supposed to...
Part of Proteintech’s early vision was to make all its own products, to the highest standards possible and to take complete responsibility for the quality of each product.